Article Type
Changed
Fri, 03/25/2022 - 09:47

Key clinical point: Modern management of rheumatoid arthritis (RA) led to a larger proportion of patients achieving remission with fewer corticosteroids and more biologics over a 7-year follow-up period.

 

Major finding: Twice as many patients with RA were in remission at 7-year follow-up vs. at 1 year. Patients achieving remission at 7 years were more likely to be using biological disease-modifying antirheumatic drugs (DMARD) and conventional DMARD (P = .02), whereas corticosteroids (P = .02) at higher doses (P = .013) were mostly prescribed to patients not achieving remission at 7 years.

 

Study details: The data come from a retrospective study of 215 patients with RA whose clinical and biological data were analyzed at 1 year (2009) and 7 years (2015).

 

Disclosures: The authors declared no source of funding or conflicts of interest.

 

Source: Larid G et al. Increased remission with fewer corticosteroids and more biologics in rheumatoid arthritis at 7-year follow-up in real-life conditions. Sci Rep. 2022;12:2563 (Feb 15). Doi: 10.1038/s41598-022-06584-y

Publications
Topics
Sections

Key clinical point: Modern management of rheumatoid arthritis (RA) led to a larger proportion of patients achieving remission with fewer corticosteroids and more biologics over a 7-year follow-up period.

 

Major finding: Twice as many patients with RA were in remission at 7-year follow-up vs. at 1 year. Patients achieving remission at 7 years were more likely to be using biological disease-modifying antirheumatic drugs (DMARD) and conventional DMARD (P = .02), whereas corticosteroids (P = .02) at higher doses (P = .013) were mostly prescribed to patients not achieving remission at 7 years.

 

Study details: The data come from a retrospective study of 215 patients with RA whose clinical and biological data were analyzed at 1 year (2009) and 7 years (2015).

 

Disclosures: The authors declared no source of funding or conflicts of interest.

 

Source: Larid G et al. Increased remission with fewer corticosteroids and more biologics in rheumatoid arthritis at 7-year follow-up in real-life conditions. Sci Rep. 2022;12:2563 (Feb 15). Doi: 10.1038/s41598-022-06584-y

Key clinical point: Modern management of rheumatoid arthritis (RA) led to a larger proportion of patients achieving remission with fewer corticosteroids and more biologics over a 7-year follow-up period.

 

Major finding: Twice as many patients with RA were in remission at 7-year follow-up vs. at 1 year. Patients achieving remission at 7 years were more likely to be using biological disease-modifying antirheumatic drugs (DMARD) and conventional DMARD (P = .02), whereas corticosteroids (P = .02) at higher doses (P = .013) were mostly prescribed to patients not achieving remission at 7 years.

 

Study details: The data come from a retrospective study of 215 patients with RA whose clinical and biological data were analyzed at 1 year (2009) and 7 years (2015).

 

Disclosures: The authors declared no source of funding or conflicts of interest.

 

Source: Larid G et al. Increased remission with fewer corticosteroids and more biologics in rheumatoid arthritis at 7-year follow-up in real-life conditions. Sci Rep. 2022;12:2563 (Feb 15). Doi: 10.1038/s41598-022-06584-y

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: RA April 2022
Gate On Date
Thu, 03/24/2022 - 00:45
Un-Gate On Date
Thu, 03/24/2022 - 00:45
Use ProPublica
CFC Schedule Remove Status
Thu, 03/24/2022 - 00:45
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article